AbbVie Inc. (ABBV)

83.54
NYSE : Health Technology
Prev Close 85.27
Day Low/High 82.76 / 85.48
52 Wk Low/High 62.66 / 91.99
Avg Volume 7.39M
Exchange NYSE
Shares Outstanding 1.48B
Market Cap 126.10B
EPS 3.70
P/E Ratio 37.40
Div & Yield 4.72 (4.91%)
4 Favorite Biotech Stock Picks for 2020

4 Favorite Biotech Stock Picks for 2020

The Medical Technology Stock Letter's top pick rose 357% in 2019.

Jim Cramer: Don't Get Sacked in This Political Football Match

Jim Cramer: Don't Get Sacked in This Political Football Match

How to prepare your portfolio and be opportunistic in the face of this geopolitical instability.

This Dividend Aristocrat Is Our Top Pick for 2020

This Dividend Aristocrat Is Our Top Pick for 2020

As it smooths out the wrinkles from 2019, this pharmaceutical manufacturer should have a healthy year.

My Pick for 2020? You Won't Believe It's Been on Your Screen All Along

My Pick for 2020? You Won't Believe It's Been on Your Screen All Along

This company made headlines in 2019, and I'm betting on it as a great play -- in many senses of the word -- for this new year.

Individual Investors Are Back! Trading Cisco: Market Recon

Individual Investors Are Back! Trading Cisco: Market Recon

It seemed to happen overnight. People watched. People listened. People cared. About what? Individual stocks.

Jim Cramer: Think Stocks Are Too Pricey? These Big Takeovers Prove They're Not

Jim Cramer: Think Stocks Are Too Pricey? These Big Takeovers Prove They're Not

We're seeing lots of companies snapping up their peers, and the market is applauding.

Cash Stashes Dwindle as Markets Crest and Powell Speaks: Market Recon

Cash Stashes Dwindle as Markets Crest and Powell Speaks: Market Recon

Plus, we preview Wednesday's Trump-Erdogan meeting and check out AbbVie's huge debt offering as well as the new Abode-Microsoft connection.

Jim Cramer: Here's the Good News About the U.S./China Trade Delay

Jim Cramer: Here's the Good News About the U.S./China Trade Delay

There are plenty of stocks that have been thrown away for several weeks because of a belief that the Fed and a trade deal will avoid a recession.

Drug Companies Are a Political Football, Trading Amgen: Market Recon

Drug Companies Are a Political Football, Trading Amgen: Market Recon

The nation enters an electoral season. The drug companies for the most part, have no friends on either side of the aisle.

Jim Cramer: Drug Stocks Are Too Cheap

Jim Cramer: Drug Stocks Are Too Cheap

These stocks are priced for total imperfection. That's just what you want.

6 Top Biopharmaceutical Stock Picks You Should Know About

6 Top Biopharmaceutical Stock Picks You Should Know About

The aging population is creating a massive tailwind for companies that provide cutting-edge health care.

The Long Decline in AbbVie Is Over

The Long Decline in AbbVie Is Over

In addition to the yield let's check out the charts of ABBV.

Jim Cramer: Where Can You Still Get Some Growth and a Big Yield?

Jim Cramer: Where Can You Still Get Some Growth and a Big Yield?

Right now, AbbVie is the best way to capitalize on the moment and on the future.

AbbVie: The Right Mixture for the Perfect Stock

AbbVie: The Right Mixture for the Perfect Stock

ABBV has a positive earnings-per-share growth, an expanding price-to-earnings multiple and dividends that could result in annual shareholder returns well above 20%.

Big Pharma Sees Pockets of Recent Insider Buying

Big Pharma Sees Pockets of Recent Insider Buying

AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.

Draghi's End Game and a 3-Way Battle Shapes Up in the Cloud: Market Recon

Draghi's End Game and a 3-Way Battle Shapes Up in the Cloud: Market Recon

Plus, Intel results crush expectations and Starbucks solidifies its comeback.

One Prescription for Uncertain Market? Gilead Sciences

One Prescription for Uncertain Market? Gilead Sciences

Use buy-write orders as a conservative way to invest in GILD in these uneasy times.

Buyout Speculation Picks Up in Biotech

Buyout Speculation Picks Up in Biotech

Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.

AbbVie Insiders Buying Shares

Stocks see a nice surge on the open on optimism around trade talks resuming between the U.S. and China, although negotiations will be ongoing for many months and no permanent resolution seems on the horizon. The U.S. PMI Manufacturing Index also cam...

Now at the Plate, Your Pinch Hitter, Bret Jensen!

It is good to be sitting in for Doug Kass here on The Daily Diary as we open trading in the second half of 2019. June ended on an up note as all the major indices drifted up last week to close out the month and quarter. The market did an admirable j...

My 3 Predictions for the Second Half of 2019

My 3 Predictions for the Second Half of 2019

Watch the Russell 2000, housing activity, and mergers and acquisitions.

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.

Final Thoughts on Allergan/AbbVie

Allergan: A Recent History

Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Despite the financial positivity, many analysts warn the deal could have hiccups ahead.

AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere

AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere

The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.

I Believe AbbVie and Allergan Need Each Other

I Believe AbbVie and Allergan Need Each Other

With no other bidder expected to emerge, this is a high risk arbitrage play.

Think AbbVie Is Overpaying for Allergan? Pfizer Offered Way More in 2015

Think AbbVie Is Overpaying for Allergan? Pfizer Offered Way More in 2015

PFE was ready to pay $160 billion until U.S. regulators blocked the deal.